UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

May 2017

UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours

Results from a published multicenter study

The results from a German multicenter study were published in the latest issue of Tumor Biology. Principal investigator was  Dr Thorsten Ecke at the Department of Urology, HELIOS Hospital, Bad Saarow.

Urine samples were analyzed with UBC® Rapid POC test and results were determined quantitatively with a reader.

Bladder cancer is one of the most costly cancer diseases, affecting around 2500 persons yearly in Sweden.

The most common method for detection of bladder cancer and for the assessment of recurrence is cystoscopy, a procedure in which an optic fiber is used for examination of the bladder.

The Swedish company IDL Biotech AB has developed a complementary test to cystoscopy – UBC® Rapid, especially useful for detection of high grade bladder cancer.

The test is already clinically documented and is in routine use in Germany.

The combination of UBC® Rapid with an objective POC-reader can enable improved risk stratification.

The new study demonstrated a very high sensitivity (71%) and specificity (94%)for high grade tumors. For patients with cancer in situ (CIS), the sensitivity was even higher (87%). The authors conclude that UBC® Rapid should be added in the diagnostics of high grade tumors and especially for CIS patients.

Notice of Annual General Meeting 2019

The shareholders of IDL Biotech AB (publ) are hereby invited to the Annual General Meeting on Tuesday, 28 May 2019, 15.00 at Redeye AB, Mäster Samuelsgatan 42, 10387 Stockholm.

IDL in the Spotlight

Spotlight has produced a short film about IDL Biotech.

IDL Biotech

Skip this intro